Email this article UNDERSTANDING STRUCTURE AND ROLE OF PD-1 RECEPTOR AND ITS LIGANDS IN CANCER IMMUNOTHERAPY
About this article
Received: 23/11/20 Revised: 05/03/21 Published: 15/03/21Authors
1. Tran Thi Thanh Huong
, TNU - University of Information and Communication Technology2. Nguyen Thi Huong Ly, TNU - University of Information and Communication Technology
3. Tran Duc Hoang, TNU - University of Information and Communication Technology
Abstract
Cancer is one of the most serious health problems and is one of the leading diseases of death around the world. The goal of this paper is to find a new method to treat cancer, therefore we have approached the PD-1 receptor and its ligands (PD-L1 and PD-L2). Our immune system will have checkpoints to guarantee that no foreign objects are allowed to enter our body. However, by many different ways, the cancer cellcan escape the body's immune system checkpoints to develop. One of the ways that cancer cells use to hide is by "fooling" the PD-1/PD-L checkpoint. Our research method is to synthesize some studies towards inhibition of the PD-1/PD-L axis, in which the previously inactivated T-lymphocytes are reactivated, resulting in increasing activities and rate of toxic T cells, helping to kill the tumor cells. This has opened up a promising new direction for clinicians in choosing new cancer treatments.
Keywords
Full Text:
PDF (Tiếng Việt)References
[1] Y. Agata, A. Kawasaki, and H. Nishimura, “Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes,” International Immunology, vol. 8, pp. 765-772, 1996.
[2] R. V. Parry, J. M. Chemnitz, and K. A. Frauwirth, “CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms,” Molecular and cell biology, vol. 25, pp. 9543-9553, 2005.
[3] J. A. Brown et al, “Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production,” Journal Immunology, vol. 170, pp. 1257-1266, 2003.
[4] H. Dong and L. Chen, “B7–H1 pathway and its role in the evasion of tumor immunity,” International Journal of Molecular Medicine, vol. 81, pp. 281-287, 2003.
[5] R. H. Thompson et al., “Tumor B7–H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up,” Cancer Research, vol. 66, pp. 3381-3385, 2006.
[6] J. C. Schwartz, X. Zhang, A. A. Fedorov, S. G. Nathenson, and S. C. Almo, “Structural basis for co-stimulation by the human CTLA-4/B7–2 complex”, Nature, vol. 410, pp. 604-608, 2001.
[7] Y. Latchman, C. R. Wood, and T. Chernova, “PD-L2 is a second ligand for PD-1 and inhibits T cell activation,” Nature Immunology, vol. 2, pp. 261-268, 2001.
[8] L. Carter, L. A. Fouser, and J. Jussif, “PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2,” Centre European. Journal Immunology., vol. 32, pp. 634-643, 2002.
[9] M. J. Butte, M. E. Keir, T. B. Phamduy, A. H. Sharpe, and G. J. Freeman, “Programmed Death-1 ligand interacts specifically with the B7–1 costimulatory molecule to inhibit T cell responses,” Immunity, vol. 27, pp. 111-122, 2007.
[10] M. IShida, Y. Iwai, and Y. Tanaka, “Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues,” Immunoogy Letter, vol. 84, pp. 57-62, 2002.
[11] E. O. Long, “Regulation of immune responses through inhibitory receptors,” Annual Review of. Immunology., vol. 17, pp. 875-904, 1999.
[12] K. M. Doan, "Evaluation of PD-L1 exposure in a patient lung cancer not small cells,” Vietnam Medical Journal, vol. 471, pp. 152-157, 2018.[13] T. T. Tran, Determine the exposure of PD-L1 in cancer patients non-small lung at K hospital, Grassroots level scientific research project, 2018.[14] M. Zhang, G. Li, and Y. Wang, "PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis," Scientific Report, vol. 7, no. 1, pp. 10255-10257, 2017.
[15] R. S. Herbst, P. Baas, and D. W. Kim, "Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial," Lancet, vol. 387(10027), pp. 1540-1550, 2016.
Refbacks
- There are currently no refbacks.